• 1.北京大學(xué)人民醫(yī)院心臟中心 （北京 100044）2.首都醫(yī)科大學(xué)附屬北京同仁醫(yī)院心血管中心（北京 100730）;

引用本文： 胡大一,楊進(jìn)剛. 推論原則和循證醫(yī)學(xué)證據(jù)：近期介入治療臨床試驗的啟示. 中國循證醫(yī)學(xué)雜志, 2007, 07(5): 333-336. doi: 復(fù)制

1. Hochman JS, Lamas GA, Buller CE, et al. Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med, 2006, 355(23): 2395-2407.
2. Lamas GA, Flaker GC, Mitchell G, et al. Effect of infarct artery patency on prognosis after acute myocardial infarction. Circulation, 1995, 92(5): 1101-1109.
3. Boden WE, O’Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med, 2007, 356(15): 1503-1516.
4. Valgimigli M, Percoco G, Malagutti P, et al. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA, 2005 , 293(17): 2109-2117.
5. Laarman GJ, Suttorp MJ, Dirksen MT, et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med, 2006, 355(11): 1105-1113.
6. Menichelli M. SESAMI: Sirolimus stent vs bare stent in acute myocardial infarction. http://www.medscape.com/viewarticle/533970.
7. Spaulding C, Henry P, Teiger E, et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med, 2006, 355(11): 1093-1104.
8. Tieraia L. Paclitaxel Stent Had Wider Lumen in Acute MI Patients http://www.tct2006.com/Dailies_TCT2006/tuesday_fulltext/Paclitaxel_Stent_Had_Wider_Lumen_in_Acute_MI_Patients.html.
9. Kahn J. TCT Daily: ESTROFA: late thrombosis not increased in DES patients: Spanish registry of drug-eluting stents shows STEMI, LAD artery lesions, significant risk factors. J Interv Cardiol, 2007, 20(1): 32.
10. Kernis SJ, Cohen DJ, Reid K, et al. Clinical outcomes associated with use of drug-eluting stents compared with bare metal stents for primary percutaneous intervention [abstract]. Am J Cardiol, 2005, 96: 47H.
11. Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation, 2006, 113(24): 2803-2809.
12. Grines CL, Cox DA, Stone GW, et al. Coronary angioplasty with or without stent implantation for acute myocardial infarction. N Engl J Med,1999, 341(26): 1949-1956.
13. Stone GW, Grines CL, Cox DA, et al. Comparison of Angioplasty with Stenting, with or without Abciximab, in Acute Myocardial Infarction. N Engl J Med, 2002, 346(13): 957-966.
14. Stone GW, Webb J, Cox DA, et al. Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction: a randomized controlled trial. JAMA, 2005, 293(9): 1063-1072.
15. Mauri L, O’Malley AJ, Popma JJ, et al. Comparison of thrombosis and restenosis risk from stent length of sirolimus-eluting stents versus bare metal stents. Am J Cardiol, 2005, 95: 1140-1145.
16. Pinto DS, Stone GW, Ellis SG, et al. Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: results from the TAXUS-IV trial. J Am Coll Cardiol, 2006, 48(1): 32-36.
17. Update to FDA Statement on Coronary Drug-Eluting Stents]http://www.fda.gov/cdrh/news/010407.html.
18. Lagerqvist B, James SK, Stenestrand U, et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med, 2007, 356(1)): 1009-1019.
19. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet, 2007, 369 (9562): 667-678.
  1. 1. Hochman JS, Lamas GA, Buller CE, et al. Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med, 2006, 355(23): 2395-2407.
  2. 2. Lamas GA, Flaker GC, Mitchell G, et al. Effect of infarct artery patency on prognosis after acute myocardial infarction. Circulation, 1995, 92(5): 1101-1109.
  3. 3. Boden WE, O’Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med, 2007, 356(15): 1503-1516.
  4. 4. Valgimigli M, Percoco G, Malagutti P, et al. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA, 2005 , 293(17): 2109-2117.
  5. 5. Laarman GJ, Suttorp MJ, Dirksen MT, et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med, 2006, 355(11): 1105-1113.
  6. 6. Menichelli M. SESAMI: Sirolimus stent vs bare stent in acute myocardial infarction. http://www.medscape.com/viewarticle/533970.
  7. 7. Spaulding C, Henry P, Teiger E, et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med, 2006, 355(11): 1093-1104.
  8. 8. Tieraia L. Paclitaxel Stent Had Wider Lumen in Acute MI Patients http://www.tct2006.com/Dailies_TCT2006/tuesday_fulltext/Paclitaxel_Stent_Had_Wider_Lumen_in_Acute_MI_Patients.html.
  9. 9. Kahn J. TCT Daily: ESTROFA: late thrombosis not increased in DES patients: Spanish registry of drug-eluting stents shows STEMI, LAD artery lesions, significant risk factors. J Interv Cardiol, 2007, 20(1): 32.
  10. 10. Kernis SJ, Cohen DJ, Reid K, et al. Clinical outcomes associated with use of drug-eluting stents compared with bare metal stents for primary percutaneous intervention [abstract]. Am J Cardiol, 2005, 96: 47H.
  11. 11. Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation, 2006, 113(24): 2803-2809.
  12. 12. Grines CL, Cox DA, Stone GW, et al. Coronary angioplasty with or without stent implantation for acute myocardial infarction. N Engl J Med,1999, 341(26): 1949-1956.
  13. 13. Stone GW, Grines CL, Cox DA, et al. Comparison of Angioplasty with Stenting, with or without Abciximab, in Acute Myocardial Infarction. N Engl J Med, 2002, 346(13): 957-966.
  14. 14. Stone GW, Webb J, Cox DA, et al. Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction: a randomized controlled trial. JAMA, 2005, 293(9): 1063-1072.
  15. 15. Mauri L, O’Malley AJ, Popma JJ, et al. Comparison of thrombosis and restenosis risk from stent length of sirolimus-eluting stents versus bare metal stents. Am J Cardiol, 2005, 95: 1140-1145.
  16. 16. Pinto DS, Stone GW, Ellis SG, et al. Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: results from the TAXUS-IV trial. J Am Coll Cardiol, 2006, 48(1): 32-36.
  17. 17. Update to FDA Statement on Coronary Drug-Eluting Stents]http://www.fda.gov/cdrh/news/010407.html.
  18. 18. Lagerqvist B, James SK, Stenestrand U, et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med, 2007, 356(1)): 1009-1019.
  19. 19. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet, 2007, 369 (9562): 667-678.